Trial Profile
Phase IB Study of Lenalidomide (Revlimid) With Liposomal Doxorubicin (Doxil) and Bevacizumab (Avastin) for Patients With Platinum Resistant Ovarian Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2014
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Bevacizumab; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Adverse reactions
- 02 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 02 Jul 2012 Actual patient number 1 added as reported by ClinicalTrials.gov.
- 02 Jul 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.